Medical Equipment, Supplies & Distribution

Page 3

Orthofix International NV gives Q1 2015 revenue guidance below analysts' estimates; gives FY 2015 guidance below analysts' estimates

Wednesday, 29 Apr 2015 04:00pm EDT

Orthofix International NV:Expects FY 2015 net sales in the range of $385 million to $390 million, representing a decline of (0.7pct) to growth of 0.6pct on a constant currency basis and a decline of 3.1pct to 4.3pct on a reported basis.Expects FY 2015 adjusted EBITDA in the range of $55 million to $58 million.Expects Q1 2015 net sales in the range of $88 million to $90 million, representing a decline of 7.1pct to 9.1pct on a constant currency basis and 10.0pct to 12.0pct on a reported basis.Q1 2015 revenue of $102 million - Thomson Reuters I/B/E/S.FY 2015 revenue of $416 million and EBITDA of $69 million - Thomson Reuters I/B/E/S.

Wright Medical Group, Inc reaffirms FY 2015 guidance

Wednesday, 29 Apr 2015 04:00pm EDT

Wright Medical Group, Inc:Continues to anticipate net sales for FY 2015 of about $325 million to $335 million, representing constant currency growth of 13pct to 16pct from FY 2014.Continues to anticipate FY 2015 adjusted EBITDA from continuing operations, as described in the GAAP to non-GAAP reconciliation provided later in this release, of negative $(22.0) million to negative $(27.0) million.Continues to anticipate adjusted earnings per share from continuing operations, including stock-based compensation, for FY 2015 of $(1.67) to $(1.77) per diluted share.FY 2015 revenue of $329 million, EBITDA of $(26.4) million and EPS of $(1.70) - Thomson Reuters I/B/E/S.

Alliqua BioMedical Inc announces pricing of public offering of common stock

Wednesday, 29 Apr 2015 08:40am EDT

Alliqua BioMedical Inc:Says pricing of an underwritten public offering of 6,593,407 shares of its common stock at a price to the public of $4.55 per share.The offering is expected to close on or about May 4, subject to customary closing conditions.Says Alliqua has granted the underwriters a 30-day option to purchase up to 989,011 additional shares of common stock to cover overallotments, if any.Says Cowen and Company, LLC and RBC Capital Markets, LLC are acting as the joint book-running managers for the offering, and Craig-Hallum Capital Group LLC is acting as co-manager.The Company intends to use the net proceeds from this offering to fund the commercial expansion of its marketed products, to pursue additional product platforms, and for working capital and general corporate purposes.

Sorin SpA gives Q2 2015 revenue guidance

Wednesday, 29 Apr 2015 08:30am EDT

Sorin SpA:Sees Q2 2015 revenues to grow by 2 pct. to 3 pct.

Stratec Biomedical comments on FY 2015 outlook and through to FY 2017 forecast

Wednesday, 29 Apr 2015 01:32am EDT

Stratec Biomedical AG:For the 2015 financial year as a whole, we expect slight sales growth compared with 2014 and a slight increase in the EBIT margin.Targets set out in our financial forecast first communicated in July 2013, which provides for average annual sales growth of eight to twelve percent through to FY 2017 accompanied by increasing profitability, remain valid.FY 2014 sales 144.86 million euros, EBIT margin 16.6 pct.FY 2015 sales estimate 158.42 million euros, EBIT margin estimate 17.1 pct - Thomson Reuters I/B/E/S.FY 2016 sales estimate 179.25 million euros - Thomson Reuters I/B/E/S.FY 2017 sales estimate 194.23 million euros - Thomson Reuters I/B/E/S.

Align Technology Inc announces $70 million accelerated stock repurchase agreement as part of previously announced $300 million program

Tuesday, 28 Apr 2015 08:16pm EDT

Align Technology Inc:Entered into accelerated stock repurchase agreement (ASR) with Morgan Stanley & Co. LLC, to repurchase $70 million of Align's common stock as part of Align's three-year, $300 million stock repurchase program announced on April 23, 2014.Align completed repurchase of first $100 million of program in first quarter of 2015.Under terms of ASR, Align has agreed to repurchase $70 million of its common stock from Morgan Stanley, with an initial delivery of about 824,000 shares.Final number of shares to be repurchased will be based on Align's volume-weighted average stock price during term of ASR transaction, less an agreed upon discount.ASR transaction is expected to be completed about three months from April 29, and will be funded with the company's cash on hand.

Exactech Inc lowers FY 2015 guidance; gives Q2 2015 guidance below analysts' estimates

Tuesday, 28 Apr 2015 04:01pm EDT

Exactech Inc:Updates FY 2015 revenue guidance to $248-$254 million.Updates FY 2015 diluted EPS target to $1.18 -- $1.24.Expects Q2 2015 revenues of $61-$63 mln.Expects Q2 2015 diluted EPS of $0.26-$0.28.FY 2015 revenue of $254 mln, EPS of $1.23 - Thomson Reuters I/B/E/S.Q2 2015 revenue of $64 mln, EPS of $0.30 - Thomson Reuters I/B/E/S.

Spotlight Innovation Inc closes $2.5 million financing

Tuesday, 28 Apr 2015 01:05pm EDT

Spotlight Innovation Inc:Says it has closed on an unsecured convertible promissory note in the gross principal amount of $2,500,000, exclusive of certain fees.The note has a maturity date of March 27, 2020, and bears interest at the rate of Prime plus 5 pct during the first 36 months, increasing to an interest of Prime plus 6 pct for the remaining 24 months.The note is convertible into shares of common stock of the company at a price of $1.50 per share.The company also issued warrants to purchase 250,000 shares of common stock of the company.The warrants have a five-year term and are exercisable into shares of common stock of the company at the greater of $1.50 or 50 pct of the average closing bid price of the company's common stock during the 20 days immediately following exercise thereof.

Stentys SA's Next-Generation of Self-Apposing Stent System receives CE Marking ahead of plan

Tuesday, 28 Apr 2015 12:17pm EDT

Stentys SA:Receives CE Marking for its new Self-Apposing stent system ahead of plan, which will allow the Company to market the new products in Europe and in all the other countries where this certification is recognized.STENTYS will officially launch Xposition S at the EuroPCR conference on May 19.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Zacks Investment Research Inc.
$10.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.